A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer. The analysis also identified hundreds of potential drug targets that could cut off a tumor’s fuel supply or interfere with its ability to synthesize essential building blocks.
The board of Irish drugmaker Elan has unanimously rejected a takeover bid from Royalty Pharma, saying the U.S. investment company's offer of $11.25 a share is much too low. Royalty last week lowered its bid for Elan from an original $12 per share offer.
Merck and Bristol-Myers Squibb will run a mid-stage clinical trial of a drug regimen designed to treat the most common type of the hepatitis C virus. The trial will study a combination of Bristol's drug daclatasvir, and Merck's MK-5172.
Researchers have devised an way to block biological signaling pathways that, when overactive, lead to many types of cancers. They've done so by disrupting the function of a mediator, or scaffold, protein that brings together key members of the pathway and promotes their interaction to stimulate cell growth and division.
EMD Serono Inc. announced the continued expansion of the company's presence in the United States, resulting in an estimated 20% increase in EMD Serono's employee base from last July to the end of 2014. The expansion will primarily take place at the site in Billerica, Mass.
The world's biggest biotech company Amgen Inc. will focus on recent results on a key experimental melanoma drug, testing of other drugs and revenue from its top-selling drugs when it reports first-quarter results after the stock market closes Tuesday.
Irish drugmaker Elan Corp. PLC said it had completed its "Dutch auction" stock repurchase, buying back $1 billion in stock for $11.25 per share. Under the modified Dutch auction, stockholders notify the company how many shares they'd like to sell and at what price within the announced range.
Federal health experts issued a split opinion on whether a long-acting testosterone injection from Endo Health Solutions is safe. A Food and Drug Administration panel voted 9-9 on the safety of Endo's Aveed, a drug designed to be injected once every 10 weeks to boost testosterone in men with abnormally low levels.
Viralytics Ltd. has finalized the clinical study report on the Phase 1 evaluation of Cavatak administered intravenously to late stage melanoma, prostate, breast, or colorectal cancer patients. Cavatak was well tolerated with some evidence of stable disease despite most patients only receiving a single dose of Cavatak.
Eli Lilly and Co. announced it has acquired two investigational positron emission tomography tracers from Siemens Medical Solutions USA Inc. The tracers are intended to image tau tangles in the brain, one of two known hallmarks of Alzheimer's disease.
A panel of respiratory experts voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of panelists felt that the Breo Ellipta inhaler is safe and effective for long-term use and to control flare ups in patients with COPD.
Acura Pharmaceuticals Inc. benefited greatly from a decision by federal regulators to block new painkillers that aren't designed to resist abuse. The company sells a decongestant called Nexafed and its abuse-deterring technology is used in Pfizer Inc.'s painkiller Oxecta.
Researchers have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy.
Allergan Inc. said that the Food and Drug Administration isn't ready to approve its inhaled migraine treatment Levadex. Allergan said the FDA is concerned about elements of the manufacturing process for Levadex. The company said it is already responding to those concerns.
Federal health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse. The Food and Drug Administration said it would not approve any generic versions of OxyContin based on the original formulation.